Cerenome, Inc. (CNSY)
2.24
-0.08
(-3.66%)
USD |
NASDAQ |
Sep 14, 10:46
Cerenome Gross Profit Margin (Quarterly) : 63.26% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 63.26% |
| March 31, 2026 | 89.40% |
| December 31, 2025 | 93.27% |
| September 30, 2025 | 93.84% |
| June 30, 2025 | 93.81% |
| March 31, 2025 | 82.91% |
| December 31, 2024 | 83.57% |
| September 30, 2024 | 84.07% |
| June 30, 2024 | 84.21% |
| March 31, 2024 | 88.91% |
| December 31, 2023 | 86.14% |
| September 30, 2023 | 84.84% |
| June 30, 2023 | 89.86% |
| March 31, 2023 | 63.04% |
| December 31, 2022 | -90.07% |
| September 30, 2022 | -68.49% |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 5.97% |
| December 31, 2018 | 91.58% |
| September 30, 2018 | 50.66% |
| June 30, 2018 | 3.34% |
| March 31, 2018 | 20.79% |
| December 31, 2017 | 4.53% |
| September 30, 2017 | -64.88% |
| June 30, 2017 | 27.04% |
| March 31, 2017 | -21.15% |
| December 31, 2016 | 35.54% |
| September 30, 2016 | 15.46% |
| June 30, 2016 | 48.05% |
| March 31, 2016 | 57.46% |
| December 31, 2015 | 49.16% |
| September 30, 2015 | 79.73% |
| June 30, 2015 | 19.70% |
| March 31, 2015 | 33.70% |
| December 31, 2014 | 42.65% |
| September 30, 2014 | 34.94% |
| June 30, 2014 | 18.07% |
| March 31, 2014 | 59.17% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Ernexa Therapeutics, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -442.0% |
| Return on Assets | -164.5% |
| Return on Invested Capital | -418.8% |
| Profit Margin (Quarterly) | -2.19K% |
| Operating Margin (Quarterly) | -2.20K% |
| Return on Net Operating Assets | -792.4% |